All News

RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
injection-green.jpg

Anakinra's Effects on COVID-19 Outcomes

d Jack Cush, MD

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote

Read Article
Physician.Solo_.paper_.EMR_.jpg

USA Ranks 11th (Last) in Healthcare Delivery

d Jack Cush, MD

Despite spending more (18%) of its gross national product on health care than its peers, the U.S.

Read Article
covid vaccine needle vaccination

COVID Vaccine Booster Effective for Transplant Recipients in Small Trial

d MedPage Today

For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Mepolizumab Dosing in Eosinophilic Granulomatosis with Polyangiitis

d Jack Cush, MD

A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome). 

Read Article
ICYMI: Can you manage FM without opioids? Study of 698 Fibromyalgia pts from a tertiary center finds 27.1% taking opioids. Opioid associated with longer Sx duration (>3 yrs), increased age, worse functional impairment & pain catastrophizing https://t.co/N1G4ZtkUE5

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has expanded the use of SHINGRIX vaccine to include adults 18 years and older who are compromised by immunodeficiency or immunosuppression caused by disease or therapy. https://t.co/Wf2mzvOQcU

Links:

Dr. John Cush RheumNow ( View Tweet)

https://t.co/VBxg9fQmt0 Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia... https://t.co/XIB7OVNCvT

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study https://t.co/XVXgEoufCw Nice data another p19 IL23 inhb - safety continues to impress

Links:

Peter Nash drpnash ( View Tweet)

New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
Biomarkers predict early ILD in systemic sclerosis: https://t.co/9z4Swjjy4p we need a biomarker for early disease!

Links:

Peter Nash drpnash ( View Tweet)

Chronologic Progression of Ankylosing Spondylitis https://t.co/ihVVystOMn https://t.co/SXhkkBgzTJ

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID Vaccine Booster Effective for Transplant Recipients in Small Trial For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed. https://t.co/iD2WFfUP3a https://t.co/eYMdocd9T4

Links:

Dr. John Cush RheumNow ( View Tweet)
A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome). https://t.co/hgeiSHhxSj https://t.co/cfi2nZGzBa

Links:

Dr. John Cush RheumNow ( View Tweet)
Symptom eval of 870 1st degree relatives of RA in PREVeNT-RA study - 5% were seropositive & 14% had incr CRP. Sleep probs (20%) & joint pain (18%) most common. Symmetrical small joint pain ~12% higher in RF+ and 11% higher w/ high CRP https://t.co/aYoLX0sZ2p

Links:

Dr. John Cush RheumNow ( View Tweet)

Interesting case report of difficult periorbital Discoid lupus erythematosus (DLE) treated with topical tofacitinib, 2%, ointment, a topical Janus kinase (JAK) 1/3 inhibitor. https://t.co/NZxUFW9ilN

Links:

Dr. John Cush RheumNow ( View Tweet)

Drs. Jack Cush, Kathryn Dao, Janet Pope, Eric Dein and Yuz Yusof discuss a number of lupus presentations as well as abstracts presented at the virtual EULAR 2021 meeting. Lupus nephritis and treat-to-remission presentations were discussed by the panel. https://t.co/dfRdeveeLp

Links:

Dr. John Cush RheumNow ( View Tweet)

85 rheumatic kids RTX treated - New hypogammaglobulinemia in 27% w/in 18 mos AND 26% w/ infections (half being serious infx). Prior pulse steriods ups risk of inx (OR 15.3) and hypogamma (OR 3.9). Hypogamm predicts risk of SIE (OR 7.9)

Dr. John Cush RheumNow ( View Tweet)

In 206 #SLE pts (mean 62 yrs) polypharmacy (≥10 meds) seen in 35%. 31% used benzodiazepines & 24% opioids. Polypharmacy greater with prednisone, comorbidity & rural. Polypharmacy assoc w/ 4X Benzo & 7X opioid use https://t.co/4U0UakoIRr

Links:

Dr. John Cush RheumNow ( View Tweet)

Takayasu's responds to Tofacitinib - 53 pts given TOF + glucocorticoids (GCs) (n=27) or MTX + GCs (n=26). At 12 mos complete remission (CR) more with TOF (88% vs 56%, p=0.02), w/ lower GC use and relapse rates ((12% vs 35%, p=0.052) https://t.co/qgziyIhKgV

Links:

Dr. John Cush RheumNow ( View Tweet)

×